Business / Finance

RSS

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the second quarter ended December 31, 2010.

5 Feb 2011

HCR to pay off existing term loan and revolving credit facilities

HCR ManorCare, Inc. has announced its intention to refinance its term loan and revolving credit facilities. The new term loan is for $400 million, and the revolving credit agreement is for $150 million.

5 Feb 2011

Lotus adds two additional stories to new Beijing headquarters building

Lotus Pharmaceuticals, Inc., a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced that it will add two additional stories to its new headquarters building in Chaoyang District, Beijing, which is currently under construction and is scheduled to be completed in the second quarter of 2011.

5 Feb 2011

NYSE Amex accepts Palatin's exchange listing compliance plan

Palatin Technologies, Inc. reported that its exchange listing compliance plan has been accepted by the NYSE Amex. Palatin has been granted an extension until May 26, 2011 to regain compliance with stockholders' equity requirements under Section 1003(a)(iii) of the NYSE Amex Company Guide and until February 28, 2011 to regain compliance with financial condition continued listing requirements under Section 1003(a)(iv).

5 Feb 2011

The Female Health Company first quarter FY2011 net revenues decrease 33%

The Female Health Company, which manufactures and markets the FC2 Female Condom, today reported its operating results for the first quarter of FY2011.

5 Feb 2011

Continucare second quarter total revenue increases 7% to $80.3 million

Continucare Corporation today reported record financial results for its second quarter of fiscal 2011.

5 Feb 2011

Onset Therapeutics announces corporate name change to Onset Dermatologics

Onset Therapeutics, a PreCision Dermatology company and a leader in the development and commercialization of novel, prescription products for the treatment of skin disorders, today announced that it has changed its corporate name to Onset Dermatologics.

5 Feb 2011

Endocyte prices initial public offering

Endocyte, Inc., a biopharmaceutical company developing targeted small molecule drug conjugates, announced today the pricing of its initial public offering of 12,500,000 shares of its common stock.

5 Feb 2011

Partek signs distribution agreement with Life Technologies

Partek Incorporated, a global leader in bioinformatics software, announced today the signing of a distribution agreement with Life Technologies Corporation, a provider of next-generation DNA sequencing technology. The agreement makes Partek Genomics Suite available through Life Technologies as a featured solution for analyzing data generated by Life Technologies' next-generation sequencing devices.

5 Feb 2011

Microsulis' Microwave Endometrial Ablation platform sold to Hologic

Microsulis Medical Limited announced this week that it has exclusively licensed to Hologic Inc all rights to its microwave technology in the gynecology and female urology fields of use.

From Hologic, Inc. 5 Feb 2011

ArtVentive announces $10,000,000 USD agreement with European financial group

ArtVentive Medical Group, announced today a ten million dollar financing agreement with a European financial group. A firm commitment for the first tranche of $1,950,000 is at $.90 per share with the remainder of the financing to be priced at not less than $.90 per share.

5 Feb 2011

AmerisourceBergen first quarter revenues increase 3% to record $19.9 billion

AmerisourceBergen Corporation today reported that in its fiscal year 2011 first quarter, ended December 31, 2010, diluted earnings per share were $0.57, a 10 percent increase. Revenue in the quarter was a record $19.9 billion, up 3 percent.

4 Feb 2011

Savient closes sale of $230M 4.75% Convertible Senior Notes due 2018

Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.

4 Feb 2011

MedQuist Holdings prices initial public offering of common stock at $8.00 per share

MedQuist Holdings Inc., formerly CBaySystems Holdings Limited, a leading provider of integrated clinical documentation solutions for the U.S. Healthcare system, today announced the pricing of its U.S. initial public offering of 4,500,000 shares of its common stock at a price to the public of $8.00 per share.

4 Feb 2011

Incisive Surgical, Innocutis sign marketing agreement for INSORB Absorbable Skin Stapler

Innocutis Medical, a dermatology company focused on novel surgical devices and specialty pharmaceuticals, is pleased to announce an exclusive marketing agreement with Incisive Surgical, for the sales and marketing rights within the dermatology market for the patented INSORB Absorbable Skin Stapler, a revolutionary new modality for skin closure.

4 Feb 2011

BG Medicine prices initial public offering of 5,000,000 shares of common stock

BG Medicine today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions. All shares are being sold by the Company.

4 Feb 2011

Accelerated completes acquisition of SPTRS, Burkam

Gryphon Investors announced today that its outpatient physical therapy platform company, Accelerated Rehabilitation Centers, has completed the acquisition of two physical therapy companies - Wisconsin based Sports Physical Therapy & Rehab Specialists and Ohio based Burkam & Associates.

4 Feb 2011

DaVita enters definitive agreement to acquire DSI Renal for $690 million

DaVita, announced that it has entered into a definitive agreement to acquire DSI Renal, for approximately $690 million, subject to adjustments. The company expects to close the transaction in the second or third quarter of this year.

4 Feb 2011

Precise Biometrics 2010 group's net sales decrease to SEK 44.9 million

Precise Biometrics AB, Year-end report for the period January - December 2010

4 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011